OZILTUS
LaunchmAbdenosumab-mobz
BLASUBCUTANEOUSINJECTABLE
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OZILTUS (denosumab-mobz) is rank ligand blocking activity [moa]. First approved in 2025.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OZILTUS (denosumab-mobz) is a monoclonal antibody that blocks RANK ligand, a key regulator of bone resorption, approved for osteoporosis, bone metastases, and multiple myeloma. It is administered subcutaneously and represents a biosimilar or follow-on biologic entry in the established RANK inhibitor class. The drug targets patients requiring bone-protective therapy across oncology and rheumatology indications.
Launch
Early-stage launch lifecycle offers opportunity to build market share in a competitive space; team expansion likely as market penetration strategy develops.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OZILTUS places you in a high-stakes competitive launch scenario where rapid market penetration and defensive positioning against Amgen's reference products are critical. Success requires strong commercial execution, payer negotiation, and physician education—offering visibility and cross-functional influence across commercial and medical teams.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.